Omada Health announced the launch of Omada for Cholesterol, a dedicated program that adds cholesterol management to its existing virtual‑care platform. The new offering builds on the company’s weight, glucose, blood pressure and GLP‑1 services, positioning Omada as a comprehensive cardiometabolic solution for employers and health plans.
Omada for Cholesterol combines human‑led coaching, medication‑adherence guidance and AI‑driven nutrition and activity support. The program is designed to lower LDL‑C levels and reduce long‑term cardiovascular risk, extending the platform’s preventive focus beyond weight and glucose control.
The launch is part of Omada’s strategy to capture a larger share of the $41.4 billion GLP‑1 market and to strengthen its competitive moat against point‑solution providers and traditional telehealth platforms. By offering a single partner for multiple cardiometabolic conditions, Omada can deepen customer relationships and increase member engagement.
Adding cholesterol care enhances Omada’s integrated platform, allowing it to meet the growing demand for between‑visit care that addresses cumulative cardiovascular risk. The flexible infrastructure that enabled the quick addition of the program also reduces customer acquisition costs and supports scalable growth across its member base.
While the announcement does not include new earnings data, it aligns with Omada’s recent financial trajectory. Preliminary Q4 2025 revenue is projected at $72–$74 million, a 50–54% year‑over‑year increase, and gross margin is expected to remain at 66%. The new program is expected to contribute to continued revenue growth and margin stability as part of the broader cardiometabolic portfolio.
CEO Sean Duffy said the launch signals strong demand for between‑visit cholesterol care and that Omada’s flexible infrastructure allowed the rapid addition of the program. Chief Medical Officer Thomas Tsang noted that cholesterol management reduces cumulative cardiovascular risk and complements existing lifestyle programs, underscoring the clinical value of the new offering.
The program’s introduction reflects Omada’s broader strategy to become a one‑stop cardiometabolic platform, leveraging AI and coaching to deliver measurable health outcomes across multiple risk factors.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.